Lento Bio

Executive Summary

Lento Bio is a preclinical-stage biotechnology company pioneering first-in-class small molecule eye drops to reverse age-related vision loss. Its lead candidate, LB-01, targets molecular crosslinks that stiffen the crystalline lens, aiming to restore natural accommodation and treat presbyopia. Unlike symptomatic treatments, Lento Bio’s approach addresses the underlying biological damage of aging. Founded in 2020 and based in San Diego, the company has advanced LB-01 to late preclinical development and is preparing for regulatory filings. While the company is still private with limited financial disclosure, its differentiated mechanism and potential to address a large unmet need in presbyopia position it as an interesting early-stage opportunity. Key risks include preclinical-to-clinical translation and competition from other lens-targeting therapies.

Upcoming Catalysts (preview)

• Q4 2026IND submission for LB-0170% success
• Q2 2027Initiation of Phase 1 clinical trial for LB-0160% success
• H1 2027Announcement of strategic partnership or funding round50% success